Research Analysts’ updated eps estimates for Thursday, October 5th:

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $60.00 target price on the stock. The analysts wrote, “HARMONY Study Initiation: Killing Multiple” Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple” birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP).””

Actinium Pharmaceuticals (NYSEMKT:ATNM) had its buy rating reaffirmed by analysts at Maxim Group. The firm currently has a $3.00 price target on the stock.

BroadSoft (NASDAQ:BSFT) had its outperform rating reiterated by analysts at William Blair.

CBOE Holdings (NASDAQ:CBOE) had its outperform rating reissued by analysts at Wells Fargo & Company. Wells Fargo & Company currently has a $120.00 price target on the stock, up from their previous price target of $106.00. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

Duerr AG (ETR:DUE) had its neutral rating reissued by analysts at DZ Bank AG.

Fibrocell Science (NASDAQ:FCSC) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $7.60 price target on the stock.

Amicus Therapeutics (NASDAQ:FOLD) had its buy rating reissued by analysts at Chardan Capital. They currently have a $18.50 price target on the stock, up from their previous price target of $16.50.

Greenbrier Companies, Inc. (The) (NYSE:GBX) had its buy rating reiterated by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a $60.00 price target on the stock, up from their previous price target of $51.00.

Ligand Pharmaceuticals (NASDAQ:LGND) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $157.00 price target on the stock.

Lamb Weston Holdings (NYSE:LW) had its buy rating reiterated by analysts at Jefferies Group LLC. They currently have a $58.00 price target on the stock.

Mylan N.V. (NASDAQ:MYL) had its market perform rating reiterated by analysts at Cowen and Company. They currently have a $36.00 price target on the stock, up from their previous price target of $30.00.

Ingevity Corp (NASDAQ:NGVT) had its overweight rating reissued by analysts at KeyCorp. The firm currently has a $75.00 price target on the stock, up from their previous price target of $70.00.

pdvWireless (NASDAQ:PDVW) had its buy rating reaffirmed by analysts at B. Riley. They currently have a $59.00 target price on the stock. The analysts wrote, “We have reviewed initial comments in the FCC’s Notice of Inquiry (NOI) regarding potential realignment of the 896-901/935-940 MHz band to create a private enterprise broadband allocation and believe the proposal remains on path to Notice of Proposed Rulemaking (NPRM) in the months following the 11/1 reply comment deadline, with the FCC ultimately approving realignment of the 896-901/935-940 MHz band to create a private enterprise broadband allocation. Initial comment deadline was 10/2. Along with PDVW, numerous stakeholders chimed in, with contributions from Critical Infrastructure Industry (CII) interests, such as railroads, refineries, and utilities, as well as from Specialized Mobile Radio (SMR) companies, private enterprises, investors, and individuals.””

PTC (NASDAQ:PMTC) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $57.00 price target on the stock.

Perrigo (NYSE:PRGO) had its buy rating reiterated by analysts at UBS AG. UBS AG currently has a $98.00 target price on the stock, up from their previous target price of $84.00.

Science Applications International Corporation (NYSE:SAIC) had its market perform rating reissued by analysts at Cowen and Company. They currently have a $72.00 price target on the stock, down from their previous price target of $75.00.

Shopify (NYSE:SHOP) (TSE:SH) had its outperform rating reissued by analysts at Robert W. Baird. Robert W. Baird currently has a $110.00 price target on the stock.

Sequans Communications (NYSE:SQNS) had its buy rating reaffirmed by analysts at Canaccord Genuity. The firm currently has a $4.25 price target on the stock, down from their previous price target of $6.00.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its market perform rating reiterated by analysts at Wells Fargo & Company.

Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.